ATOSSA THERAPEUTICS, INC. (ATOS) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-14

Key Insights

Director Chen Shu-Chih received a grant of 10,000 restricted stock units vesting on May 12, 2027, representing a $0 transaction price typical of equity compensation rather than open market purchases.
Chen maintains indirect beneficial ownership of 1,483 shares through Ensisheim Partners, LLC (shared with Dr. Steven C. Quay), indicating a modest overall equity stake in the company despite his director role.
This filing represents routine equity compensation to a company director with no material insider buying or selling activity, suggesting stable insider confidence but no significant new investment conviction.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-14

Director Remmel H. Lawrence acquired 10,000 restricted stock units (RSUs) on May 12, 2026, vesting one year later, indicating company confidence in long-term value and insider alignment with shareholders.
The grant was at $0 price with zero consideration, representing compensation rather than market purchases, which is typical for director equity awards but shows no discretionary buying signal.
Lawrence's total beneficial ownership increased to 10,683 shares following this transaction, suggesting a relatively modest equity stake despite his director position at the company.

Filed: 2026-05-14

Director Jonathan Finn received a grant of 10,000 restricted stock units (RSUs) on May 12, 2026, vesting one year later, indicating continued equity compensation alignment with company performance.
Following this transaction, Finn's total beneficial ownership increased to 11,666 shares, demonstrating a meaningful insider stake in ATOS despite the relatively modest grant size.
The RSU grant at $0 exercise price represents a direct equity incentive rather than a market-based purchase, suggesting the company is using equity compensation as a retention mechanism for board members.

Filed: 2026-05-14

Director Stephen J. Galli acquired 10,000 restricted stock units (RSUs) on 05/12/2026 at no cost, representing a standard equity compensation grant with a one-year vesting schedule, indicating routine executive compensation rather than discretionary market purchases.
Following this transaction, Galli's total beneficial ownership increased to 10,006 shares, suggesting a relatively modest shareholding position for a director-level insider at the company.
The grant of RSUs with $0 exercise price and future vesting is a non-cash compensation arrangement common in biotech companies, which does not signal strong insider confidence in near-term stock appreciation but rather reflects standard equity incentive practices.

Filed: 2026-05-14

Director Tessa Cigler acquired 10,000 restricted stock units (RSUs) on May 12, 2026, with a grant price of $0, indicating a compensation grant rather than a market purchase.
The RSUs vest on the first anniversary of May 12, 2026, representing a one-year vesting schedule that aligns executive compensation with longer-term company performance.
This is a routine equity compensation transaction for a director, showing continued engagement with the company but providing no signal regarding insider confidence in near-term stock price movements.

Filed: 2026-03-31

The reporting person, Steven C. Quay, who is the President and CEO of Atossa Therapeutics, Inc. (ATOS), acquired 65,000 shares of the company's common stock through a grant of restricted stock units (RSUs).
The number of securities reported has been adjusted to reflect a 1-for-15 reverse stock split that the company recently effected.
Quay also holds an indirect beneficial ownership of 1,483 shares of the company's common stock through his ownership of Ensisheim Partners, LLC.

Filed: 2026-01-22

The CEO of Atossa Therapeutics, Inc. (ATOS) acquired a significant number of 325,203 shares of the company's common stock, indicating their confidence in the company's future prospects.
The CEO was also granted 950,000 stock options with an exercise price of $0.603, suggesting potential upside for the company's share price.
The CEO holds a significant ownership stake in the company, both directly and indirectly through their ownership in Ensisheim Partners, LLC, aligning their interests with those of other shareholders.

Other reports for ATOSSA THERAPEUTICS, INC.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.